# Petco Health & Wellness Company, Inc.: financial statements, quarterly

WOOF · Nasdaq · CIK 1826470 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Jan 30

Pages: [Overview](/companies/woof.md) · [Financials](/companies/woof/financials.md) · [Filings](/companies/woof/filings.md) · [Insiders](/companies/woof/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/woof/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-10-28) | Q4 FY2023 (2024-02-03) | Q1 FY2024 (2024-05-04) | Q2 FY2024 (2024-08-03) | Q3 FY2024 (2024-11-02) | Q4 FY2024 (2025-02-01) | Q1 FY2025 (2025-05-03) | Q2 FY2025 (2025-08-02) | Q3 FY2025 (2025-11-01) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-05-02) | Q2 FY2026 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,494](/filings/0000950170-24-134077.md) | [1,674 d](/filings/0001193125-26-106114.md) | [1,529](/filings/0000950170-25-083057.md) | [1,524](/filings/0001826470-25-000015.md) | [1,511](/filings/0001193125-25-309620.md) | [1,552 d](/filings/0001193125-26-106114.md) | [1,493](/filings/0001193125-26-259944.md) | [1,489](/filings/0001193125-26-383639.md) | [1,464](/filings/0001193125-25-309620.md) | [1,515 d](/filings/0001193125-26-106114.md) | [1,497](/filings/0001193125-26-259944.md) | [1,489](/filings/0001193125-26-383639.md) |
| Cost of revenue | $m | [944](/filings/0000950170-24-134077.md) | [1,068 d](/filings/0001193125-26-106114.md) | [950](/filings/0000950170-25-083057.md) | [943](/filings/0001826470-25-000015.md) | [936](/filings/0001193125-25-309620.md) | [963 d](/filings/0001193125-26-106114.md) | [923](/filings/0001193125-26-259944.md) | [903](/filings/0001193125-26-383639.md) | [895](/filings/0001193125-25-309620.md) | [934 d](/filings/0001193125-26-106114.md) | [922](/filings/0001193125-26-259944.md) | [898](/filings/0001193125-26-383639.md) |
| Gross profit | $m | [550](/filings/0000950170-24-134077.md) | [606 d](/filings/0001193125-26-106114.md) | [579](/filings/0000950170-25-083057.md) | [581](/filings/0001826470-25-000015.md) | [576](/filings/0001193125-25-309620.md) | [589 d](/filings/0001193125-26-106114.md) | [570](/filings/0001193125-26-259944.md) | [585](/filings/0001193125-26-383639.md) | [569](/filings/0001193125-25-309620.md) | [581 d](/filings/0001193125-26-106114.md) | [574](/filings/0001193125-26-259944.md) | [591](/filings/0001193125-26-383639.md) |
| Selling, general and administrative | $m | [560](/filings/0000950170-24-134077.md) | [606 d](/filings/0001193125-26-106114.md) | [595](/filings/0000950170-25-083057.md) | [578](/filings/0001826470-25-000015.md) | [572](/filings/0001193125-25-309620.md) | [572 d](/filings/0001193125-26-106114.md) | [554](/filings/0001193125-26-259944.md) | [542](/filings/0001193125-26-383639.md) | [540](/filings/0001193125-25-309620.md) | [549 d](/filings/0001193125-26-106114.md) | [550](/filings/0001193125-26-259944.md) | [543](/filings/0001193125-26-383639.md) |
| Operating income | $m | [(1,232)](/filings/0000950170-24-134077.md) | [0.2 d](/filings/0001193125-26-106114.md) | [(16.8)](/filings/0000950170-25-083057.md) | [2.5](/filings/0001826470-25-000015.md) | [4.0](/filings/0001193125-25-309620.md) | [17.4 d](/filings/0001193125-26-106114.md) | [16.4](/filings/0001193125-26-259944.md) | [43.0](/filings/0001193125-26-383639.md) | [29.2](/filings/0001193125-25-309620.md) | [31.9 d](/filings/0001193125-26-106114.md) | [24.6](/filings/0001193125-26-259944.md) | [47.8](/filings/0001193125-26-383639.md) |
| Interest expense | $m | [36.6](/filings/0000950170-23-068810.md) | [39.7 d](/filings/0000950170-24-040516.md) | [36.8](/filings/0000950170-25-083057.md) | [36.8](/filings/0001826470-25-000015.md) | [35.8](/filings/0001193125-25-309620.md) | [34.1 d](/filings/0001193125-26-106114.md) | [33.5](/filings/0000950170-25-083057.md) | [33.3](/filings/0001826470-25-000015.md) | [32.8](/filings/0001193125-25-309620.md) | [31.6 d](/filings/0001193125-26-106114.md) | [32.8](/filings/0001193125-26-259944.md) | [32.6](/filings/0001193125-26-383639.md) |
| Income tax | $m | [(22.9)](/filings/0000950170-24-134077.md) | [(10.4) d](/filings/0001193125-26-106114.md) | [(4.5)](/filings/0000950170-25-083057.md) | [(4.7)](/filings/0001826470-25-000015.md) | [(0.9)](/filings/0001193125-25-309620.md) | [2.5 d](/filings/0001193125-26-106114.md) | [0.5](/filings/0001193125-26-259944.md) | [0.7](/filings/0001193125-26-383639.md) | [(6.3)](/filings/0001193125-25-309620.md) | [11.3 d](/filings/0001193125-26-106114.md) | [2.2](/filings/0001193125-26-259944.md) | [(15.7)](/filings/0001193125-26-383639.md) |
| Net income | $m | [(1,241)](/filings/0000950170-24-134077.md) | [(22.6) d](/filings/0001193125-26-106114.md) | [(46.5)](/filings/0000950170-25-083057.md) | [(24.8)](/filings/0001826470-25-000015.md) | [(16.7)](/filings/0001193125-25-309620.md) | [(13.8) d](/filings/0001193125-26-106114.md) | [(11.7)](/filings/0001193125-26-259944.md) | [14.0](/filings/0001193125-26-383639.md) | [9.3](/filings/0001193125-25-309620.md) | [(2.6) d](/filings/0001193125-26-106114.md) | [(15.1)](/filings/0001193125-26-259944.md) | [38.7](/filings/0001193125-26-383639.md) |
| Diluted EPS | $ per share | [(4.63)](/filings/0000950170-24-134077.md) | not reported | [(0.17)](/filings/0000950170-25-083057.md) | [(0.09)](/filings/0001826470-25-000015.md) | [(0.06)](/filings/0001193125-25-309620.md) | not reported | [(0.04)](/filings/0001193125-26-259944.md) | [0.05](/filings/0001193125-26-383639.md) | [0.03](/filings/0001193125-25-309620.md) | not reported | [(0.05)](/filings/0001193125-26-259944.md) | [0.13](/filings/0001193125-26-383639.md) |
| Basic EPS | $ per share | [(4.63)](/filings/0000950170-24-134077.md) | not reported | [(0.17)](/filings/0000950170-25-083057.md) | [(0.09)](/filings/0001826470-25-000015.md) | [(0.06)](/filings/0001193125-25-309620.md) | not reported | [(0.04)](/filings/0001193125-26-259944.md) | [0.05](/filings/0001193125-26-383639.md) | [0.03](/filings/0001193125-25-309620.md) | not reported | [(0.05)](/filings/0001193125-26-259944.md) | [0.14](/filings/0001193125-26-383639.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-28) | FY2023 (2024-02-03) | Q1 FY2024 (2024-05-04) | Q2 FY2024 (2024-08-03) | Q3 FY2024 (2024-11-02) | FY2024 (2025-02-01) | Q1 FY2025 (2025-05-03) | Q2 FY2025 (2025-08-02) | Q3 FY2025 (2025-11-01) | FY2025 (2026-01-31) | Q1 FY2026 (2026-05-02) | Q2 FY2026 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [140](/filings/0000950170-23-068810.md) | [125](/filings/0000950170-25-047693.md) | [89.7](/filings/0000950170-24-069337.md) | [128](/filings/0000950170-24-105211.md) | [117](/filings/0000950170-24-134077.md) | [166](/filings/0001193125-26-106114.md) | [133](/filings/0000950170-25-083057.md) | [189](/filings/0001826470-25-000015.md) | [237](/filings/0001193125-25-309620.md) | [257](/filings/0001193125-26-383639.md) | [167](/filings/0001193125-26-259944.md) | [293](/filings/0001193125-26-383639.md) |
| Current assets | $m | [1,008](/filings/0000950170-23-068810.md) | [952](/filings/0000950170-25-047693.md) | [904](/filings/0000950170-24-069337.md) | [942](/filings/0000950170-24-105211.md) | [932](/filings/0000950170-24-134077.md) | [974](/filings/0001193125-26-106114.md) | [920](/filings/0000950170-25-083057.md) | [940](/filings/0001826470-25-000015.md) | [1,007](/filings/0001193125-25-309620.md) | [1,020](/filings/0001193125-26-383639.md) | [961](/filings/0001193125-26-259944.md) | [1,053](/filings/0001193125-26-383639.md) |
| Total assets | $m | [5,427](/filings/0000950170-23-068810.md) | [5,363](/filings/0000950170-25-047693.md) | [5,259](/filings/0000950170-24-069337.md) | [5,277](/filings/0000950170-24-105211.md) | [5,211](/filings/0000950170-24-134077.md) | [5,194](/filings/0001193125-26-106114.md) | [5,121](/filings/0000950170-25-083057.md) | [5,153](/filings/0001826470-25-000015.md) | [5,205](/filings/0001193125-25-309620.md) | [5,173](/filings/0001193125-26-383639.md) | [5,085](/filings/0001193125-26-259944.md) | [5,167](/filings/0001193125-26-383639.md) |
| Current liabilities | $m | [1,115](/filings/0000950170-23-068810.md) | [1,113](/filings/0000950170-25-047693.md) | [1,069](/filings/0000950170-24-069337.md) | [1,118](/filings/0000950170-24-105211.md) | [1,114](/filings/0000950170-24-134077.md) | [1,139](/filings/0001193125-26-106114.md) | [1,083](/filings/0000950170-25-083057.md) | [1,059](/filings/0001826470-25-000015.md) | [1,103](/filings/0001193125-25-309620.md) | [1,134](/filings/0001193125-26-383639.md) | [1,130](/filings/0001193125-26-259944.md) | [1,166](/filings/0001193125-26-383639.md) |
| Total liabilities | $m | [4,234](/filings/0000950170-23-068810.md) | [4,179](/filings/0000950170-25-047693.md) | [4,097](/filings/0000950170-24-069337.md) | [4,145](/filings/0000950170-24-105211.md) | [4,089](/filings/0000950170-24-134077.md) | [4,081](/filings/0001193125-26-106114.md) | [4,014](/filings/0000950170-25-083057.md) | [4,014](/filings/0001826470-25-000015.md) | [4,048](/filings/0001193125-25-309620.md) | [4,009](/filings/0001193125-26-383639.md) | [3,929](/filings/0001193125-26-259944.md) | [3,960](/filings/0001193125-26-383639.md) |
| Long-term debt | $m | [1,575](/filings/0000950170-23-068810.md) | [1,576](/filings/0000950170-25-047693.md) | [1,574](/filings/0000950170-24-069337.md) | [1,576](/filings/0000950170-24-105211.md) | [1,577](/filings/0000950170-24-134077.md) | [1,578](/filings/0001193125-26-106114.md) | [1,579](/filings/0000950170-25-083057.md) | [1,581](/filings/0001826470-25-000015.md) | [1,582](/filings/0001193125-25-309620.md) | [1,489](/filings/0001193125-26-106114.md) | not reported | not reported |
| Shareholders' equity | $m | [1,193](/filings/0000950170-23-068810.md) | [1,184](/filings/0000950170-25-047693.md) | [1,162](/filings/0000950170-24-069337.md) | [1,131](/filings/0000950170-24-105211.md) | [1,123](/filings/0000950170-24-134077.md) | [1,114](/filings/0001193125-26-383639.md) | [1,107](/filings/0001193125-26-383639.md) | [1,139](/filings/0001193125-26-383639.md) | [1,158](/filings/0001193125-25-309620.md) | [1,164](/filings/0001193125-26-383639.md) | [1,155](/filings/0001193125-26-383639.md) | [1,207](/filings/0001193125-26-383639.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-10-28) | Q4 FY2023 (2024-02-03) | Q1 FY2024 (2024-05-04) | Q2 FY2024 (2024-08-03) | Q3 FY2024 (2024-11-02) | Q4 FY2024 (2025-02-01) | Q1 FY2025 (2025-05-03) | Q2 FY2025 (2025-08-02) | Q3 FY2025 (2025-11-01) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-05-02) | Q2 FY2026 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [34.4 d](/filings/0000950170-24-134077.md) | [47.0 d](/filings/0001193125-26-106114.md) | [(8.4)](/filings/0000950170-25-083057.md) | [69.4 d](/filings/0001826470-25-000015.md) | [20.7 d](/filings/0001193125-25-309620.md) | [96.0 d](/filings/0001193125-26-106114.md) | [(15.5)](/filings/0001193125-26-259944.md) | [85.9 d](/filings/0001193125-26-383639.md) | [90.1 d](/filings/0001193125-25-309620.md) | [154 d](/filings/0001193125-26-106114.md) | [(31.0)](/filings/0001193125-26-259944.md) | [162 d](/filings/0001193125-26-383639.md) |
| Capital expenditure | $m | [62.5 d](/filings/0000950170-24-134077.md) | [49.1 d](/filings/0001193125-26-106114.md) | [32.6](/filings/0000950170-25-083057.md) | [27.4 d](/filings/0001826470-25-000015.md) | [31.0 d](/filings/0001193125-25-309620.md) | [36.9 d](/filings/0001193125-26-106114.md) | [28.4](/filings/0001193125-26-259944.md) | [32.1 d](/filings/0001193125-26-383639.md) | [29.4 d](/filings/0001193125-25-309620.md) | [37.1 d](/filings/0001193125-26-106114.md) | [38.2](/filings/0001193125-26-259944.md) | [31.6 d](/filings/0001193125-26-383639.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-29) | Q1 FY2023 (2023-04-29) | Q2 FY2023 (2023-07-29) | Q3 FY2023 (2023-10-28) | Q1 FY2024 (2024-05-04) | Q2 FY2024 (2024-08-03) | Q3 FY2024 (2024-11-02) | Q1 FY2025 (2025-05-03) | Q2 FY2025 (2025-08-02) | Q3 FY2025 (2025-11-01) | Q1 FY2026 (2026-05-02) | Q2 FY2026 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [266](/filings/0000950170-23-068810.md) | [0.3](/filings/0000950170-24-069337.md) | [0.3](/filings/0000950170-24-105211.md) | [268](/filings/0000950170-24-134077.md) | [270](/filings/0000950170-25-083057.md) | [273](/filings/0001826470-25-000015.md) | [274](/filings/0001193125-25-309620.md) | [278](/filings/0001193125-26-259944.md) | [286](/filings/0001193125-26-383639.md) | [288](/filings/0001193125-25-309620.md) | [284](/filings/0001193125-26-259944.md) | [290](/filings/0001193125-26-383639.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.